Detection of Pulmonary Embolism With CECT

Phase 4CompletedNCT00351754

Bracco Diagnostics, Inc120 enrolled

Overview

To compare the vascular enhancement of the two contrast agents in pulmonary Multi-detector CTA

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

DIAGNOSTIC

Masking

DOUBLE

Enrollment

120

Conditions

Pulmonary Embolism

Interventions

IsovueDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients 18 yrs or older * With suspected PE * Referred for MDCTA of pulmonary arteries * Signed informed consent Exclusion Criteria: * Pregnant and lactating females * History of hypersensitivity to iodinated contrast agents * Hyperthyroidism or pheochromocytoma * Severe CHF * Renal impairment * Weight greater than 300 lbs * Pacemaker * Swan Ganz catheter * Defibrillator or other intrathoracic metallic vascular device * Received an investigational compound within 30 days of being in the study

Locations (1)

Bracco Diagnostics, Inc.

Princeton, New Jersey, United States

Outcomes

Primary Outcomes

Hounsfield Units (HU) measured at various levels of pulmonary arteries

Secondary Outcomes

Presence of artifacts; global enhancement

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.